GSK plc has entered into a definitive agreement to acquire Boston-based biopharmaceutical firm Nuvalent, Inc. for $10.6 billion, a deal aimed at securing two late-stage, targeted non-small cell lung cancer (NSCLC) therapies. The acquisition, expected to close in the third quarter of 2026, grants GSK rights to ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib, both of which are currently under US FDA review.
Why GSK is targeting the lung cancer market
GSK is pivoting toward precision oncology to address the efficacy and tolerability limitations of current lung cancer standards of care. According to GSK, the acquisition of Nuvalent provides an immediate platform to expand its footprint in NSCLC, particularly by complementing its existing B7-H3 antibody-drug conjugate, Ris-Rez, which is currently in phase III development.
The deal centers on Nuvalent’s focus on kinase inhibitors. These assets are designed to provide higher target selectivity and better blood-brain barrier penetration than existing therapies. By acquiring these candidates, GSK aims to improve treatment durability for patients with specific genetic alterations, a strategy CEO Luke Miels described as a "multi-product deal" intended to fill clinical gaps in efficacy.
How the $10.6 billion deal impacts shareholders
GSK will initiate a tender offer to acquire all outstanding Nuvalent shares at $124 per share in cash, a 40% premium over the company’s last closing price. The company expects the acquisition to be accretive to sales and core operating profit starting in 2027, with core EPS accretion anticipated by 2029.
Despite the significant capital outlay, GSK stated it will maintain its current dividend policy and investment-grade credit rating. The transaction will be funded through a combination of cash and new debt facilities. GSK management confirmed that the acquisition does not alter its 2026 guidance, which projects 7-9% growth in core operating profit and core EPS.
Did you know?
Patients with ROS1- and ALK-altered NSCLC are often non-smoking adults between the ages of 40 and 50. This specific demographic often requires long-term treatment options that prioritize quality of life alongside tumor suppression.
What to expect from the drug pipeline
The two lead assets, zidesamtinib and neladalkib, have already received FDA Breakthrough Therapy and Orphan Drug Designations. According to regulatory filings, target decision dates for these therapies are set for September and November 2026, respectively.
Nuvalent’s third clinical asset, a HER2 inhibitor known as NVL-330, is currently in phase I trials. Beyond these, the acquisition includes a preclinical pipeline built on Nuvalent’s structure-based drug design platform. According to Nuvalent CEO James Porter, the collaboration with physician-scientists was critical in accelerating the clinical profile of these inhibitors, and he expects GSK’s infrastructure to support their eventual commercialization.
Frequently Asked Questions
What are the primary benefits of the Nuvalent acquisition for GSK?
The acquisition provides GSK with potential best-in-class ROS1 and ALK inhibitors for NSCLC, which could launch as early as 2026, and strengthens its overall lung cancer portfolio ahead of the loss of exclusivity for its HIV treatment, dolutegravir.
How does this deal affect GSK’s financial guidance?
GSK maintains its 2026 guidance of 7-9% growth. While the deal is expected to cause low single-digit percentage dilution to core EPS through 2028, it is projected to contribute to revenue growth starting in 2027.
What happens to Nuvalent’s existing royalty agreements?
GSK will assume Nuvalent’s existing revenue-sharing arrangements, which include low-single-digit royalty payments to Royalty Pharma and Deerfield.
Pro Tip: For investors tracking the biopharma sector, watch for the FDA’s decisions on zidesamtinib and neladalkib in late 2026, as these milestones will determine the speed at which these therapies reach the market and impact GSK’s revenue projections.
Are you interested in how precision medicine is changing cancer care? Subscribe to our oncology newsletter for weekly updates on clinical trial data and major pharmaceutical mergers.
